

# ASSOCIATION OF MEDICAL DIAGNOSTICS MANUFACTURERS ANNUAL MEETING

## “TEN TIPS FOR IVD MANUFACTURERS”

APRIL 17-18, 2013, BETHESDA, MD

Jeffrey N. Gibbs

Director

Hyman, Phelps & McNamara, P.C.

[jgibbs@hpm.com](mailto:jgibbs@hpm.com)

# 1. The Times They are A-Changin' – or Changed

- ▣ Statute - FDASIA
- ▣ Regulations - Registration
- ▣ Policies – A flurry of new and proposed guidance documents
- ▣ FDA's expectations – Regularly evolving, often without notice

The past is not necessarily prologue

## 2. Be Careful Out There

- ▣ Details matter
  - Credibility is key in FDA interactions
- ▣ Errors undermine credibility
  - Internal inconsistencies within documents
  - Inconsistency between statements in submission and study reports
  - Faulty assumptions – or making assumptions
  - Mathematical errors
  - Ambiguous or confusing writing

Haste makes waste – and creates delays

# 3. What are Your Intentions?

- ▣ Intended use is fundamental to submission and strategy
  - PMA/de novo/510(k)?
  - How much data?
  - What kind of data?
- ▣ Study design and intended use must match
  - Particularly tricky for banked specimens or retrospective studies
  - An intended use/study design mismatch can doom the submission
- ▣ Intended use must be established at early stage

Words matter, and the words of intended use may matter most of all

## 4. Be Analytical

- ▣ OIR puts a great emphasis on analytical tests
- ▣ Good clinical performance necessary but not sufficient
- ▣ Make sure do necessary analytical studies and do them correctly
  - Keep up with changing standards, e.g., new CLSI guidelines or FDA expectations

Analyze your analytical plan and execute it properly

# 5. Avoid IVD Isolationism

- ▣ IVD regulatory regime unique in many ways
- ▣ But IVDs are a subset of devices and subject to device regulatory requirements
  - Enhancement/Improvement draft guidance
  - Changes to 510(k)'d devices
  - Refuse to Accept/File
  - Risk/Benefit for PMA/de novo

Think locally (IVD), act globally (devices)

## 6. Listen Up

- ▣ OIR does give advice
  - Conferences, e.g., AMDM
  - Pre-submission meetings
  - Written feedback
  - Review memoranda
- ▣ Do not ignore it
  - Reduce chance of success
  - Can irk OIR, e.g., “As we previously advised, we recommend that you [ *fill in the blank* ]”

What we have here is a failure to communicate

# 7. Be Appealing?

- ▣ OIR is not always right
- ▣ FDASIA + Guidance Document = faster appeals
  - Appeals had been impractical because of delays; now rapid
- ▣ Changes affect timing, not biases built into system
- ▣ Appeal to Division Director and then OIR Director
- ▣ Dilemma: Little time (30 days) to decide to appeal or work together

Know when to hold 'em and when to fold 'em



# 8. Kwalitiy Counts

- ▣ Quality matter at all stages
  - Analytical
  - Clinical
  - Submission
  - Manufacturing
  - Meeting presentation
  - Regulatory Decision-making
  - Health Hazard Evaluations
  - Consultants
- ▣ There are multiple ways in which quality shortcomings can hurt

## 8. Quality Counts (cont'd)

- ▣ Bad Advice: “Make it as perfect as possible consistent with the rapidity of construction demanded.” – Central Pacific Railroad, 1866
- ▣ More Bad Advice: “I thought we had better take *high ground* and confine ourselves to the law until we are where we can make more to break it than keep it.” – Collis Huntington

## 8. Kwality Counts (cont'd)



# 9. Statistically Speaking

- ▣ Statistics play a large role in many submissions
- ▣ Statistical issues can preclude clearance/ approval
- ▣ Get statistical help at an early stage
- ▣ Use someone who speaks “statistics”
  - Statistical debates arcane, complex, and critical

99% of people (CI 97%-101%) don't really understand statistics

## 9. Statistically Speaking (cont'd)

- ▣ “But perhaps the bigger problem is the way that Fisher’s statistical philosophy tends to conceive of the world. It emphasizes the objective purity of the experiment – every hypothesis could be tested to a perfect conclusion if only enough data were collected. However, in order to achieve that purity, it denies the need for Bayesian priors or any other sort of messy real-world context.”

- Nate Silver, *The Signal and the Noise, Why So Many Predictions Fail – but Some Don’t*, 2012

# 10. Freedom of Speech

- ▣ Evaluation is First Amendment law
- ▣ Washington Legal Foundation – reprints
- ▣ Sorrell – information
- ▣ Caronia – off-label promotion
- ▣ Tobacco labeling
- ▣ Off-label speech may be constitutionally protected
- ▣ But: false or misleading speech is not
  - Material omissions can be false or misleading
  - Not affirmatively stating what is off-label?
- ▣ Bigger topic: IVDs = Information (sort of)

Think before you speak